http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 11 Jun 2026 13:21:17 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Insulet+Corporation+%28PODD%29+PT+Lowered+to+%24219+at+Truist+Securities/26634813.html <p>Truist Securities analyst Richard Newitter lowered the price target on Insulet Corporation (NASDAQ: PODD) to $219.00 (from $250.00) while maintaining a Buy rating.</p><p>The analyst comments "Our $219 PT ($250 prior) is based on a 4x EV/Sales on our 2027 est. revenue, which would reflect a 0.8x discount to the peer group average of high-growth profitable companies ex-Intuitive Surgical which trade at 4.8x/4.4x 2026/2027. We apply a discount to peers given looming competition in the patch pump space and longer term worries about the impact of GLP-1s on the terminal value. Should that not materialize as feared, given above-peer rev/profit growth http://www.streetinsider.com/Analyst+PT+Change/Insulet+Corporation+%28PODD%29+PT+Lowered+to+%24219+at+Truist+Securities/26634813.html Thu, 11 Jun 2026 13:21:17 -0400 PODD http://www.streetinsider.com/Analyst+Comments/Insulet+Corporation+%28PODD%29+PT+Lowered+to+%24219+at+Truist+Securities/26634813.html <p>Truist Securities analyst Richard Newitter lowered the price target on Insulet Corporation (NASDAQ: PODD) to $219.00 (from $250.00) while maintaining a Buy rating.</p><p>The analyst comments "Our $219 PT ($250 prior) is based on a 4x EV/Sales on our 2027 est. revenue, which would reflect a 0.8x discount to the peer group average of high-growth profitable companies ex-Intuitive Surgical which trade at 4.8x/4.4x 2026/2027. We apply a discount to peers given looming competition in the patch pump space and longer term worries about the impact of GLP-1s on the terminal value. Should that not materialize as feared, given above-peer rev/profit growth http://www.streetinsider.com/Analyst+Comments/Insulet+Corporation+%28PODD%29+PT+Lowered+to+%24219+at+Truist+Securities/26634813.html Thu, 11 Jun 2026 13:21:17 -0400 PODD http://www.streetinsider.com/Corporate+News/Insulet+reports+positive+trial+data+for+next-generation+diabetes+systems/26612822.html <p>Insulet Corporation (NASDAQ: PODD) announced results from two clinical studies evaluating its next-generation automated insulin delivery systems at the American Diabetes Association's 86th Scientific Sessions in New Orleans.</p><p>The STRIVE pivotal trial tested the Omnipod 6 algorithm in 132 participants, including 98 with type 1 diabetes and 34 with type 2 diabetes across various age groups. The randomized crossover study compared Omnipod 6 at a 100 mg/dL target glucose level against the current Omnipod 5 system at 110 mg/dL over four-week periods.</p><p>Results showed improved glucose control with Omnipod 6. For type 1 diabetes patients aged 14 and older, time in tight http://www.streetinsider.com/Corporate+News/Insulet+reports+positive+trial+data+for+next-generation+diabetes+systems/26612822.html Sat, 06 Jun 2026 07:02:30 -0400 PODD http://www.streetinsider.com/Press+Releases/Insulet+Reveals+New+Data+Supporting+Breakthrough+Omnipod%C2%AE+6+and+Fully+Closed-Loop+AID+Systems+Designed+to+Improve+Outcomes%2C+Reduce+Effort%2C+and+Unlock+Barriers+to+Care/26612820.html <ul class="bwlistdisc"> <li> <b><i>STRIVE pivotal trial shows Omnipod 6 achieved strong glycemic outcomes with fewer boluses, across age groups and diabetes types</i></b> </li> <li> <b><i>EVOLUTION 3 feasibility study demonstrates improved time in range using a fully closed-loop system for type 2 diabetes that automatically adjusts insulin with no user settings</i></b> </li> </ul> <p> ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.omnipod.com%2F&amp;esheet=54547785&amp;newsitemid=20260606260055&amp;lan=en-US&amp;anchor=tubeless+insulin+pump&amp;index=1&amp;md5=a57211e5021bf1c03f9745648f49648d" shape="rect">tubeless insulin pump</a> technology with its Omnipod® brand of products, today announced new clinical results highlighting the next breakthroughs in tubeless Automated Insulin Delivery (AID) systems. The data and growing body of evidence not http://www.streetinsider.com/Press+Releases/Insulet+Reveals+New+Data+Supporting+Breakthrough+Omnipod%C2%AE+6+and+Fully+Closed-Loop+AID+Systems+Designed+to+Improve+Outcomes%2C+Reduce+Effort%2C+and+Unlock+Barriers+to+Care/26612820.html Sat, 06 Jun 2026 07:00:00 -0400 A.14647822 A.20822773 O.00766700 O.00823282 O.20370956 PODD http://www.streetinsider.com/Press+Releases/Insulet+Reveals+New+Data+Supporting+Breakthrough+Omnipod%C2%AE+6+and+Fully+Closed-Loop+AID+Systems+Designed+to+Improve+Outcomes%2C+Reduce+Effort%2C+and+Unlock+Barriers+to+Care/26612820.html <ul class="bwlistdisc"> <li> <b><i>STRIVE pivotal trial shows Omnipod 6 achieved strong glycemic outcomes with fewer boluses, across age groups and diabetes types</i></b> </li> <li> <b><i>EVOLUTION 3 feasibility study demonstrates improved time in range using a fully closed-loop system for type 2 diabetes that automatically adjusts insulin with no user settings</i></b> </li> </ul> <p> ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.omnipod.com%2F&amp;esheet=54547785&amp;newsitemid=20260606260055&amp;lan=en-US&amp;anchor=tubeless+insulin+pump&amp;index=1&amp;md5=a57211e5021bf1c03f9745648f49648d" shape="rect">tubeless insulin pump</a> technology with its Omnipod® brand of products, today announced new clinical results highlighting the next breakthroughs in tubeless Automated Insulin Delivery (AID) systems. The data and growing body of evidence not http://www.streetinsider.com/Press+Releases/Insulet+Reveals+New+Data+Supporting+Breakthrough+Omnipod%C2%AE+6+and+Fully+Closed-Loop+AID+Systems+Designed+to+Improve+Outcomes%2C+Reduce+Effort%2C+and+Unlock+Barriers+to+Care/26612820.html Sat, 06 Jun 2026 07:00:00 -0400 A.14647822 A.20822773 O.00766700 O.00823282 O.20370956 PODD http://www.streetinsider.com/Press+Releases/Insulet+Reveals+New+Data+Supporting+Breakthrough+Omnipod%C2%AE+6+and+Fully+Closed-Loop+AID+Systems+Designed+to+Improve+Outcomes%2C+Reduce+Effort%2C+and+Unlock+Barriers+to+Care/26612820.html <ul class="bwlistdisc"> <li> <b><i>STRIVE pivotal trial shows Omnipod 6 achieved strong glycemic outcomes with fewer boluses, across age groups and diabetes types</i></b> </li> <li> <b><i>EVOLUTION 3 feasibility study demonstrates improved time in range using a fully closed-loop system for type 2 diabetes that automatically adjusts insulin with no user settings</i></b> </li> </ul> <p> ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.omnipod.com%2F&amp;esheet=54547785&amp;newsitemid=20260606260055&amp;lan=en-US&amp;anchor=tubeless+insulin+pump&amp;index=1&amp;md5=a57211e5021bf1c03f9745648f49648d" shape="rect">tubeless insulin pump</a> technology with its Omnipod® brand of products, today announced new clinical results highlighting the next breakthroughs in tubeless Automated Insulin Delivery (AID) systems. The data and growing body of evidence not http://www.streetinsider.com/Press+Releases/Insulet+Reveals+New+Data+Supporting+Breakthrough+Omnipod%C2%AE+6+and+Fully+Closed-Loop+AID+Systems+Designed+to+Improve+Outcomes%2C+Reduce+Effort%2C+and+Unlock+Barriers+to+Care/26612820.html Sat, 06 Jun 2026 07:00:00 -0400 A.14647822 A.20822773 O.00766700 O.00823282 O.20370956 PODD http://www.streetinsider.com/Press+Releases/Insulet+Reveals+New+Data+Supporting+Breakthrough+Omnipod%C2%AE+6+and+Fully+Closed-Loop+AID+Systems+Designed+to+Improve+Outcomes%2C+Reduce+Effort%2C+and+Unlock+Barriers+to+Care/26612820.html <ul class="bwlistdisc"> <li> <b><i>STRIVE pivotal trial shows Omnipod 6 achieved strong glycemic outcomes with fewer boluses, across age groups and diabetes types</i></b> </li> <li> <b><i>EVOLUTION 3 feasibility study demonstrates improved time in range using a fully closed-loop system for type 2 diabetes that automatically adjusts insulin with no user settings</i></b> </li> </ul> <p> ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.omnipod.com%2F&amp;esheet=54547785&amp;newsitemid=20260606260055&amp;lan=en-US&amp;anchor=tubeless+insulin+pump&amp;index=1&amp;md5=a57211e5021bf1c03f9745648f49648d" shape="rect">tubeless insulin pump</a> technology with its Omnipod® brand of products, today announced new clinical results highlighting the next breakthroughs in tubeless Automated Insulin Delivery (AID) systems. The data and growing body of evidence not http://www.streetinsider.com/Press+Releases/Insulet+Reveals+New+Data+Supporting+Breakthrough+Omnipod%C2%AE+6+and+Fully+Closed-Loop+AID+Systems+Designed+to+Improve+Outcomes%2C+Reduce+Effort%2C+and+Unlock+Barriers+to+Care/26612820.html Sat, 06 Jun 2026 07:00:00 -0400 A.14647822 A.20822773 O.00766700 O.00823282 O.20370956 PODD http://www.streetinsider.com/Press+Releases/Insulet+Reveals+New+Data+Supporting+Breakthrough+Omnipod%C2%AE+6+and+Fully+Closed-Loop+AID+Systems+Designed+to+Improve+Outcomes%2C+Reduce+Effort%2C+and+Unlock+Barriers+to+Care/26612820.html <ul class="bwlistdisc"> <li> <b><i>STRIVE pivotal trial shows Omnipod 6 achieved strong glycemic outcomes with fewer boluses, across age groups and diabetes types</i></b> </li> <li> <b><i>EVOLUTION 3 feasibility study demonstrates improved time in range using a fully closed-loop system for type 2 diabetes that automatically adjusts insulin with no user settings</i></b> </li> </ul> <p> ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.omnipod.com%2F&amp;esheet=54547785&amp;newsitemid=20260606260055&amp;lan=en-US&amp;anchor=tubeless+insulin+pump&amp;index=1&amp;md5=a57211e5021bf1c03f9745648f49648d" shape="rect">tubeless insulin pump</a> technology with its Omnipod® brand of products, today announced new clinical results highlighting the next breakthroughs in tubeless Automated Insulin Delivery (AID) systems. The data and growing body of evidence not http://www.streetinsider.com/Press+Releases/Insulet+Reveals+New+Data+Supporting+Breakthrough+Omnipod%C2%AE+6+and+Fully+Closed-Loop+AID+Systems+Designed+to+Improve+Outcomes%2C+Reduce+Effort%2C+and+Unlock+Barriers+to+Care/26612820.html Sat, 06 Jun 2026 07:00:00 -0400 A.14647822 A.20822773 O.00766700 O.00823282 O.20370956 PODD http://www.streetinsider.com/Press+Releases/Insulet+Reveals+New+Data+Supporting+Breakthrough+Omnipod%C2%AE+6+and+Fully+Closed-Loop+AID+Systems+Designed+to+Improve+Outcomes%2C+Reduce+Effort%2C+and+Unlock+Barriers+to+Care/26612820.html <ul class="bwlistdisc"> <li> <b><i>STRIVE pivotal trial shows Omnipod 6 achieved strong glycemic outcomes with fewer boluses, across age groups and diabetes types</i></b> </li> <li> <b><i>EVOLUTION 3 feasibility study demonstrates improved time in range using a fully closed-loop system for type 2 diabetes that automatically adjusts insulin with no user settings</i></b> </li> </ul> <p> ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.omnipod.com%2F&amp;esheet=54547785&amp;newsitemid=20260606260055&amp;lan=en-US&amp;anchor=tubeless+insulin+pump&amp;index=1&amp;md5=a57211e5021bf1c03f9745648f49648d" shape="rect">tubeless insulin pump</a> technology with its Omnipod® brand of products, today announced new clinical results highlighting the next breakthroughs in tubeless Automated Insulin Delivery (AID) systems. The data and growing body of evidence not http://www.streetinsider.com/Press+Releases/Insulet+Reveals+New+Data+Supporting+Breakthrough+Omnipod%C2%AE+6+and+Fully+Closed-Loop+AID+Systems+Designed+to+Improve+Outcomes%2C+Reduce+Effort%2C+and+Unlock+Barriers+to+Care/26612820.html Sat, 06 Jun 2026 07:00:00 -0400 A.14647822 A.20822773 O.00766700 O.00823282 O.20370956 PODD http://www.streetinsider.com/Business+Wire/Insulet+Reveals+New+Data+Supporting+Breakthrough+Omnipod%C2%AE+6+and+Fully+Closed-Loop+AID+Systems+Designed+to+Improve+Outcomes%2C+Reduce+Effort%2C+and+Unlock+Barriers+to+Care/26612820.html <ul class="bwlistdisc"> <li> <b><i>STRIVE pivotal trial shows Omnipod 6 achieved strong glycemic outcomes with fewer boluses, across age groups and diabetes types</i></b> </li> <li> <b><i>EVOLUTION 3 feasibility study demonstrates improved time in range using a fully closed-loop system for type 2 diabetes that automatically adjusts insulin with no user settings</i></b> </li> </ul> <p> ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.omnipod.com%2F&amp;esheet=54547785&amp;newsitemid=20260606260055&amp;lan=en-US&amp;anchor=tubeless+insulin+pump&amp;index=1&amp;md5=a57211e5021bf1c03f9745648f49648d" shape="rect">tubeless insulin pump</a> technology with its Omnipod® brand of products, today announced new clinical results highlighting the next breakthroughs in tubeless Automated Insulin Delivery (AID) systems. The data and growing body of evidence not http://www.streetinsider.com/Business+Wire/Insulet+Reveals+New+Data+Supporting+Breakthrough+Omnipod%C2%AE+6+and+Fully+Closed-Loop+AID+Systems+Designed+to+Improve+Outcomes%2C+Reduce+Effort%2C+and+Unlock+Barriers+to+Care/26612820.html Sat, 06 Jun 2026 07:00:00 -0400 A.14647822 A.20822773 O.00766700 O.00823282 O.20370956 PODD http://www.streetinsider.com/Business+Wire/Insulet+Reveals+New+Data+Supporting+Breakthrough+Omnipod%C2%AE+6+and+Fully+Closed-Loop+AID+Systems+Designed+to+Improve+Outcomes%2C+Reduce+Effort%2C+and+Unlock+Barriers+to+Care/26612820.html <ul class="bwlistdisc"> <li> <b><i>STRIVE pivotal trial shows Omnipod 6 achieved strong glycemic outcomes with fewer boluses, across age groups and diabetes types</i></b> </li> <li> <b><i>EVOLUTION 3 feasibility study demonstrates improved time in range using a fully closed-loop system for type 2 diabetes that automatically adjusts insulin with no user settings</i></b> </li> </ul> <p> ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.omnipod.com%2F&amp;esheet=54547785&amp;newsitemid=20260606260055&amp;lan=en-US&amp;anchor=tubeless+insulin+pump&amp;index=1&amp;md5=a57211e5021bf1c03f9745648f49648d" shape="rect">tubeless insulin pump</a> technology with its Omnipod® brand of products, today announced new clinical results highlighting the next breakthroughs in tubeless Automated Insulin Delivery (AID) systems. The data and growing body of evidence not http://www.streetinsider.com/Business+Wire/Insulet+Reveals+New+Data+Supporting+Breakthrough+Omnipod%C2%AE+6+and+Fully+Closed-Loop+AID+Systems+Designed+to+Improve+Outcomes%2C+Reduce+Effort%2C+and+Unlock+Barriers+to+Care/26612820.html Sat, 06 Jun 2026 07:00:00 -0400 A.14647822 A.20822773 O.00766700 O.00823282 O.20370956 PODD http://www.streetinsider.com/Business+Wire/Insulet+Reveals+New+Data+Supporting+Breakthrough+Omnipod%C2%AE+6+and+Fully+Closed-Loop+AID+Systems+Designed+to+Improve+Outcomes%2C+Reduce+Effort%2C+and+Unlock+Barriers+to+Care/26612820.html <ul class="bwlistdisc"> <li> <b><i>STRIVE pivotal trial shows Omnipod 6 achieved strong glycemic outcomes with fewer boluses, across age groups and diabetes types</i></b> </li> <li> <b><i>EVOLUTION 3 feasibility study demonstrates improved time in range using a fully closed-loop system for type 2 diabetes that automatically adjusts insulin with no user settings</i></b> </li> </ul> <p> ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.omnipod.com%2F&amp;esheet=54547785&amp;newsitemid=20260606260055&amp;lan=en-US&amp;anchor=tubeless+insulin+pump&amp;index=1&amp;md5=a57211e5021bf1c03f9745648f49648d" shape="rect">tubeless insulin pump</a> technology with its Omnipod® brand of products, today announced new clinical results highlighting the next breakthroughs in tubeless Automated Insulin Delivery (AID) systems. The data and growing body of evidence not http://www.streetinsider.com/Business+Wire/Insulet+Reveals+New+Data+Supporting+Breakthrough+Omnipod%C2%AE+6+and+Fully+Closed-Loop+AID+Systems+Designed+to+Improve+Outcomes%2C+Reduce+Effort%2C+and+Unlock+Barriers+to+Care/26612820.html Sat, 06 Jun 2026 07:00:00 -0400 A.14647822 A.20822773 O.00766700 O.00823282 O.20370956 PODD http://www.streetinsider.com/Business+Wire/Insulet+Reveals+New+Data+Supporting+Breakthrough+Omnipod%C2%AE+6+and+Fully+Closed-Loop+AID+Systems+Designed+to+Improve+Outcomes%2C+Reduce+Effort%2C+and+Unlock+Barriers+to+Care/26612820.html <ul class="bwlistdisc"> <li> <b><i>STRIVE pivotal trial shows Omnipod 6 achieved strong glycemic outcomes with fewer boluses, across age groups and diabetes types</i></b> </li> <li> <b><i>EVOLUTION 3 feasibility study demonstrates improved time in range using a fully closed-loop system for type 2 diabetes that automatically adjusts insulin with no user settings</i></b> </li> </ul> <p> ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.omnipod.com%2F&amp;esheet=54547785&amp;newsitemid=20260606260055&amp;lan=en-US&amp;anchor=tubeless+insulin+pump&amp;index=1&amp;md5=a57211e5021bf1c03f9745648f49648d" shape="rect">tubeless insulin pump</a> technology with its Omnipod® brand of products, today announced new clinical results highlighting the next breakthroughs in tubeless Automated Insulin Delivery (AID) systems. The data and growing body of evidence not http://www.streetinsider.com/Business+Wire/Insulet+Reveals+New+Data+Supporting+Breakthrough+Omnipod%C2%AE+6+and+Fully+Closed-Loop+AID+Systems+Designed+to+Improve+Outcomes%2C+Reduce+Effort%2C+and+Unlock+Barriers+to+Care/26612820.html Sat, 06 Jun 2026 07:00:00 -0400 A.14647822 A.20822773 O.00766700 O.00823282 O.20370956 PODD http://www.streetinsider.com/Business+Wire/Insulet+Reveals+New+Data+Supporting+Breakthrough+Omnipod%C2%AE+6+and+Fully+Closed-Loop+AID+Systems+Designed+to+Improve+Outcomes%2C+Reduce+Effort%2C+and+Unlock+Barriers+to+Care/26612820.html <ul class="bwlistdisc"> <li> <b><i>STRIVE pivotal trial shows Omnipod 6 achieved strong glycemic outcomes with fewer boluses, across age groups and diabetes types</i></b> </li> <li> <b><i>EVOLUTION 3 feasibility study demonstrates improved time in range using a fully closed-loop system for type 2 diabetes that automatically adjusts insulin with no user settings</i></b> </li> </ul> <p> ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.omnipod.com%2F&amp;esheet=54547785&amp;newsitemid=20260606260055&amp;lan=en-US&amp;anchor=tubeless+insulin+pump&amp;index=1&amp;md5=a57211e5021bf1c03f9745648f49648d" shape="rect">tubeless insulin pump</a> technology with its Omnipod® brand of products, today announced new clinical results highlighting the next breakthroughs in tubeless Automated Insulin Delivery (AID) systems. The data and growing body of evidence not http://www.streetinsider.com/Business+Wire/Insulet+Reveals+New+Data+Supporting+Breakthrough+Omnipod%C2%AE+6+and+Fully+Closed-Loop+AID+Systems+Designed+to+Improve+Outcomes%2C+Reduce+Effort%2C+and+Unlock+Barriers+to+Care/26612820.html Sat, 06 Jun 2026 07:00:00 -0400 A.14647822 A.20822773 O.00766700 O.00823282 O.20370956 PODD http://www.streetinsider.com/Business+Wire/Insulet+Reveals+New+Data+Supporting+Breakthrough+Omnipod%C2%AE+6+and+Fully+Closed-Loop+AID+Systems+Designed+to+Improve+Outcomes%2C+Reduce+Effort%2C+and+Unlock+Barriers+to+Care/26612820.html <ul class="bwlistdisc"> <li> <b><i>STRIVE pivotal trial shows Omnipod 6 achieved strong glycemic outcomes with fewer boluses, across age groups and diabetes types</i></b> </li> <li> <b><i>EVOLUTION 3 feasibility study demonstrates improved time in range using a fully closed-loop system for type 2 diabetes that automatically adjusts insulin with no user settings</i></b> </li> </ul> <p> ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.omnipod.com%2F&amp;esheet=54547785&amp;newsitemid=20260606260055&amp;lan=en-US&amp;anchor=tubeless+insulin+pump&amp;index=1&amp;md5=a57211e5021bf1c03f9745648f49648d" shape="rect">tubeless insulin pump</a> technology with its Omnipod® brand of products, today announced new clinical results highlighting the next breakthroughs in tubeless Automated Insulin Delivery (AID) systems. The data and growing body of evidence not http://www.streetinsider.com/Business+Wire/Insulet+Reveals+New+Data+Supporting+Breakthrough+Omnipod%C2%AE+6+and+Fully+Closed-Loop+AID+Systems+Designed+to+Improve+Outcomes%2C+Reduce+Effort%2C+and+Unlock+Barriers+to+Care/26612820.html Sat, 06 Jun 2026 07:00:00 -0400 A.14647822 A.20822773 O.00766700 O.00823282 O.20370956 PODD http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INSULET+CORP++++++++++++++For%3A+Jun+03++Filed+by%3A+STONESIFER+TIMOTHY+C./26606079.html si-local-file:///var/storage/secattach/20260604/26606079.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INSULET+CORP++++++++++++++For%3A+Jun+03++Filed+by%3A+STONESIFER+TIMOTHY+C./26606079.html Thu, 04 Jun 2026 16:26:00 -0400 O.00766700 PODD http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INSULET+CORP++++++++++++++For%3A+Jun+03++Filed+by%3A+STONESIFER+TIMOTHY+C./26606079.html si-local-file:///var/storage/secattach/20260604/26606079.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INSULET+CORP++++++++++++++For%3A+Jun+03++Filed+by%3A+STONESIFER+TIMOTHY+C./26606079.html Thu, 04 Jun 2026 16:26:00 -0400 O.00766700 PODD http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INSULET+CORP++++++++++++++For%3A+Jun+03++Filed+by%3A+BORIO+LUCIANA/26606054.html si-local-file:///var/storage/secattach/20260604/26606054.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INSULET+CORP++++++++++++++For%3A+Jun+03++Filed+by%3A+BORIO+LUCIANA/26606054.html Thu, 04 Jun 2026 16:23:00 -0400 O.00766700 PODD http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INSULET+CORP++++++++++++++For%3A+Jun+03++Filed+by%3A+BORIO+LUCIANA/26606054.html si-local-file:///var/storage/secattach/20260604/26606054.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INSULET+CORP++++++++++++++For%3A+Jun+03++Filed+by%3A+BORIO+LUCIANA/26606054.html Thu, 04 Jun 2026 16:23:00 -0400 O.00766700 PODD http://www.streetinsider.com/Press+Releases/Insulet+to+Spotlight+New+Data+and+Innovations+Demonstrating+How+Omnipod%C2%AE+Simplifies+Diabetes+Management+and+Delivers+Strong+Clinical+Outcomes+at+the+American+Diabetes+Association+86th+Scientific+Sess/26602271.html <ul class="bwlistdisc"> <li> <b><i>Presentations will feature next generation Omnipod innovations designed to reduce user effort, new algorithm data, and clinical evidence demonstrating improved time in range</i></b> </li> <li> <b><i>Insulet-led sessions will highlight how patient-centered design and strong clinical performance is helping redefine Automated Insulin Delivery (AID) across type 1 and type 2 diabetes</i></b> </li> </ul> <p> ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.omnipod.com%2F&amp;esheet=54547060&amp;newsitemid=20260604228498&amp;lan=en-US&amp;anchor=tubeless+insulin+pump+technology&amp;index=1&amp;md5=b3294d0176ecfd56eb4ea1e393aa4d19" shape="rect">tubeless insulin pump technology</a> with its Omnipod® brand of products, today announced its planned activities during the American Diabetes Association (ADA) 86th Scientific Sessions, taking place June 5 – 8, 2026 http://www.streetinsider.com/Press+Releases/Insulet+to+Spotlight+New+Data+and+Innovations+Demonstrating+How+Omnipod%C2%AE+Simplifies+Diabetes+Management+and+Delivers+Strong+Clinical+Outcomes+at+the+American+Diabetes+Association+86th+Scientific+Sess/26602271.html Thu, 04 Jun 2026 07:00:00 -0400 A.14647822 A.20822773 A.28110669 A.32537045 O.00766700 O.00823282 O.05014938 O.20370956 O.48401414 PODD http://www.streetinsider.com/Press+Releases/Insulet+to+Spotlight+New+Data+and+Innovations+Demonstrating+How+Omnipod%C2%AE+Simplifies+Diabetes+Management+and+Delivers+Strong+Clinical+Outcomes+at+the+American+Diabetes+Association+86th+Scientific+Sess/26602271.html <ul class="bwlistdisc"> <li> <b><i>Presentations will feature next generation Omnipod innovations designed to reduce user effort, new algorithm data, and clinical evidence demonstrating improved time in range</i></b> </li> <li> <b><i>Insulet-led sessions will highlight how patient-centered design and strong clinical performance is helping redefine Automated Insulin Delivery (AID) across type 1 and type 2 diabetes</i></b> </li> </ul> <p> ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.omnipod.com%2F&amp;esheet=54547060&amp;newsitemid=20260604228498&amp;lan=en-US&amp;anchor=tubeless+insulin+pump+technology&amp;index=1&amp;md5=b3294d0176ecfd56eb4ea1e393aa4d19" shape="rect">tubeless insulin pump technology</a> with its Omnipod® brand of products, today announced its planned activities during the American Diabetes Association (ADA) 86th Scientific Sessions, taking place June 5 – 8, 2026 http://www.streetinsider.com/Press+Releases/Insulet+to+Spotlight+New+Data+and+Innovations+Demonstrating+How+Omnipod%C2%AE+Simplifies+Diabetes+Management+and+Delivers+Strong+Clinical+Outcomes+at+the+American+Diabetes+Association+86th+Scientific+Sess/26602271.html Thu, 04 Jun 2026 07:00:00 -0400 A.14647822 A.20822773 A.28110669 A.32537045 O.00766700 O.00823282 O.05014938 O.20370956 O.48401414 PODD http://www.streetinsider.com/Press+Releases/Insulet+to+Spotlight+New+Data+and+Innovations+Demonstrating+How+Omnipod%C2%AE+Simplifies+Diabetes+Management+and+Delivers+Strong+Clinical+Outcomes+at+the+American+Diabetes+Association+86th+Scientific+Sess/26602271.html <ul class="bwlistdisc"> <li> <b><i>Presentations will feature next generation Omnipod innovations designed to reduce user effort, new algorithm data, and clinical evidence demonstrating improved time in range</i></b> </li> <li> <b><i>Insulet-led sessions will highlight how patient-centered design and strong clinical performance is helping redefine Automated Insulin Delivery (AID) across type 1 and type 2 diabetes</i></b> </li> </ul> <p> ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.omnipod.com%2F&amp;esheet=54547060&amp;newsitemid=20260604228498&amp;lan=en-US&amp;anchor=tubeless+insulin+pump+technology&amp;index=1&amp;md5=b3294d0176ecfd56eb4ea1e393aa4d19" shape="rect">tubeless insulin pump technology</a> with its Omnipod® brand of products, today announced its planned activities during the American Diabetes Association (ADA) 86th Scientific Sessions, taking place June 5 – 8, 2026 http://www.streetinsider.com/Press+Releases/Insulet+to+Spotlight+New+Data+and+Innovations+Demonstrating+How+Omnipod%C2%AE+Simplifies+Diabetes+Management+and+Delivers+Strong+Clinical+Outcomes+at+the+American+Diabetes+Association+86th+Scientific+Sess/26602271.html Thu, 04 Jun 2026 07:00:00 -0400 A.14647822 A.20822773 A.28110669 A.32537045 O.00766700 O.00823282 O.05014938 O.20370956 O.48401414 PODD http://www.streetinsider.com/Press+Releases/Insulet+to+Spotlight+New+Data+and+Innovations+Demonstrating+How+Omnipod%C2%AE+Simplifies+Diabetes+Management+and+Delivers+Strong+Clinical+Outcomes+at+the+American+Diabetes+Association+86th+Scientific+Sess/26602271.html <ul class="bwlistdisc"> <li> <b><i>Presentations will feature next generation Omnipod innovations designed to reduce user effort, new algorithm data, and clinical evidence demonstrating improved time in range</i></b> </li> <li> <b><i>Insulet-led sessions will highlight how patient-centered design and strong clinical performance is helping redefine Automated Insulin Delivery (AID) across type 1 and type 2 diabetes</i></b> </li> </ul> <p> ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.omnipod.com%2F&amp;esheet=54547060&amp;newsitemid=20260604228498&amp;lan=en-US&amp;anchor=tubeless+insulin+pump+technology&amp;index=1&amp;md5=b3294d0176ecfd56eb4ea1e393aa4d19" shape="rect">tubeless insulin pump technology</a> with its Omnipod® brand of products, today announced its planned activities during the American Diabetes Association (ADA) 86th Scientific Sessions, taking place June 5 – 8, 2026 http://www.streetinsider.com/Press+Releases/Insulet+to+Spotlight+New+Data+and+Innovations+Demonstrating+How+Omnipod%C2%AE+Simplifies+Diabetes+Management+and+Delivers+Strong+Clinical+Outcomes+at+the+American+Diabetes+Association+86th+Scientific+Sess/26602271.html Thu, 04 Jun 2026 07:00:00 -0400 A.14647822 A.20822773 A.28110669 A.32537045 O.00766700 O.00823282 O.05014938 O.20370956 O.48401414 PODD http://www.streetinsider.com/Press+Releases/Insulet+to+Spotlight+New+Data+and+Innovations+Demonstrating+How+Omnipod%C2%AE+Simplifies+Diabetes+Management+and+Delivers+Strong+Clinical+Outcomes+at+the+American+Diabetes+Association+86th+Scientific+Sess/26602271.html <ul class="bwlistdisc"> <li> <b><i>Presentations will feature next generation Omnipod innovations designed to reduce user effort, new algorithm data, and clinical evidence demonstrating improved time in range</i></b> </li> <li> <b><i>Insulet-led sessions will highlight how patient-centered design and strong clinical performance is helping redefine Automated Insulin Delivery (AID) across type 1 and type 2 diabetes</i></b> </li> </ul> <p> ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.omnipod.com%2F&amp;esheet=54547060&amp;newsitemid=20260604228498&amp;lan=en-US&amp;anchor=tubeless+insulin+pump+technology&amp;index=1&amp;md5=b3294d0176ecfd56eb4ea1e393aa4d19" shape="rect">tubeless insulin pump technology</a> with its Omnipod® brand of products, today announced its planned activities during the American Diabetes Association (ADA) 86th Scientific Sessions, taking place June 5 – 8, 2026 http://www.streetinsider.com/Press+Releases/Insulet+to+Spotlight+New+Data+and+Innovations+Demonstrating+How+Omnipod%C2%AE+Simplifies+Diabetes+Management+and+Delivers+Strong+Clinical+Outcomes+at+the+American+Diabetes+Association+86th+Scientific+Sess/26602271.html Thu, 04 Jun 2026 07:00:00 -0400 A.14647822 A.20822773 A.28110669 A.32537045 O.00766700 O.00823282 O.05014938 O.20370956 O.48401414 PODD http://www.streetinsider.com/Press+Releases/Insulet+to+Spotlight+New+Data+and+Innovations+Demonstrating+How+Omnipod%C2%AE+Simplifies+Diabetes+Management+and+Delivers+Strong+Clinical+Outcomes+at+the+American+Diabetes+Association+86th+Scientific+Sess/26602271.html <ul class="bwlistdisc"> <li> <b><i>Presentations will feature next generation Omnipod innovations designed to reduce user effort, new algorithm data, and clinical evidence demonstrating improved time in range</i></b> </li> <li> <b><i>Insulet-led sessions will highlight how patient-centered design and strong clinical performance is helping redefine Automated Insulin Delivery (AID) across type 1 and type 2 diabetes</i></b> </li> </ul> <p> ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.omnipod.com%2F&amp;esheet=54547060&amp;newsitemid=20260604228498&amp;lan=en-US&amp;anchor=tubeless+insulin+pump+technology&amp;index=1&amp;md5=b3294d0176ecfd56eb4ea1e393aa4d19" shape="rect">tubeless insulin pump technology</a> with its Omnipod® brand of products, today announced its planned activities during the American Diabetes Association (ADA) 86th Scientific Sessions, taking place June 5 – 8, 2026 http://www.streetinsider.com/Press+Releases/Insulet+to+Spotlight+New+Data+and+Innovations+Demonstrating+How+Omnipod%C2%AE+Simplifies+Diabetes+Management+and+Delivers+Strong+Clinical+Outcomes+at+the+American+Diabetes+Association+86th+Scientific+Sess/26602271.html Thu, 04 Jun 2026 07:00:00 -0400 A.14647822 A.20822773 A.28110669 A.32537045 O.00766700 O.00823282 O.05014938 O.20370956 O.48401414 PODD